|
Rich Pharmaceuticals, Inc. (RCHA) |
|
|
|
RCHA's Operating Income Growth by Quarter and Year
Rich Pharmaceuticals,'s Operating Income results by quarter and year
Select the Comparisons :
|
|
Select the Ratio:
|
Operating Income Growth Y/Y▼
|
Operating Income Growth Y/Y▼
|
RCHA Operating Income (in millions $) |
FY 2018 |
FY 2017 |
FY 2016 |
FY 2015 |
IV Quarter |
March |
-0.31
|
-0.34
|
-0.26
|
-1.21
|
III Quarter |
December |
-0.33
|
-0.21
|
-0.30
|
-1.36
|
II Quarter |
September |
-0.22
|
-0.18
|
-0.23
|
-0.52
|
I Quarter |
June |
-0.47
|
-0.22
|
-0.33
|
-0.52
|
FY |
|
-1.33
|
-0.95
|
-1.12
|
-3.61
|
RCHA Operating Income fourth quarter 2018 Y/Y Growth Comment |
Rich Pharmaceuticals, Inc. in the fourth quarter 2018 recorded Operating Loss of $ -0.31 millions.
According to the results reported in the fourth quarter 2018, Rich Pharmaceuticals, Inc. achieved the best Operating Income growth in Biotechnology & Pharmaceuticals industry. While Rich Pharmaceuticals, Inc.' s Operating Income no change of % ranks overall at the positon no. in the fourth quarter 2018.
Explain Operating Income growth
|
RCHA Operating Income ( Y/Y Growth %) |
2018
|
2017 |
2016 |
2015 |
IV Quarter |
March |
- |
- |
- |
- |
III Quarter |
December |
- |
- |
- |
- |
II Quarter |
September |
- |
- |
- |
- |
I Quarter |
June |
- |
- |
- |
- |
FY |
|
- |
- |
- |
- |
RCHA Operating Income (Quarter on Quarter Growth %) |
2018
|
2017 |
2016 |
2015 |
IV Quarter |
March |
- |
- |
- |
- |
III Quarter |
December |
- |
- |
- |
- |
II Quarter |
September |
- |
- |
- |
- |
I Quarter |
June |
- |
- |
- |
- |
FY (Year on Year) |
|
- |
- |
- |
- |
Operating Income Y/Y Growth Statistics |
High |
Average |
Low |
0 % |
0 % |
0 % |
|
|
|
|
Operating Income Y/Y Growth Statistics |
High |
Average |
Low |
0 % |
0 % |
0 % |
|
|
|
|
Operating Income by Quarter for the Fiscal Years 2015, 2016, 2017, 2018 |
Rich Pharmaceuticals,'s Q/Q Operating Income Growth
Operating Income Q/Q Growth Statistics |
High |
Average |
Low |
0 % |
0 % |
0 % |
|
|
|
RCHA's IV. Quarter Q/Q Operating Income Comment |
Even if Rich Pharmaceuticals, Inc. in the IV. Quarter 2018 admitted Operating Loss of $ -0.31 millions, it should be said, that those numbers point to improvement compare to the -0.33 millions in the third quarter.
Within Biotechnology & Pharmaceuticals industry Rich Pharmaceuticals, Inc. achieved highest sequential Operating Income growth. While Rich Pharmaceuticals,'s Operating Income growth quarter on quarter, overall rank is . |
|
|
Operating Income Q/Q Growth Statistics |
High |
Average |
Low |
0 % |
0 % |
0 % |
|
|
|
RCHA's IV. Quarter Q/Q Operating Income Comment |
Despite the fact, that Rich Pharmaceuticals, Inc. in the IV. Quarter 2018 admitted Operating Loss of $ -0.31 millions, some analyst point out, that those numbers are slight up side relative to the -0.33 millions in the third quarter.
Within Biotechnology & Pharmaceuticals industry Rich Pharmaceuticals, Inc. achieved highest sequential Operating Income growth. While Rich Pharmaceuticals,'s Operating Income growth quarter on quarter, overall rank is . |
|
Rich Pharmaceuticals,'s 12 Months Operating Income Growth Year on Year
Operating Income TTM Growth |
12 Months Ending (Mar 31 2018) |
12 Months Ending (Dec 31 2017) |
12 Months Ending (Sep 30 2017) |
12 Months Ending (Jun 30 2017) |
12 Months Ending (Mar 31 2017) |
Cumulative Operating Income 12 Months Ending |
$ -1.34 |
$ -1.37 |
$ -1.24 |
$ -1.21 |
$ -0.95 |
Y / Y Operating Income Growth (TTM) |
- |
- |
- |
- |
- |
Year on Year Operating Income Growth Overall
Ranking |
# |
# |
# |
# |
# |
Seqeuential Operating Income Change (TTM) |
- |
- |
- |
- |
- |
Seq. Operating Income Growth (TTM) Overall
Ranking |
# |
# |
# |
# |
# |
Cumulative Operating Income growth
Comment |
Rich Pharmaceuticals, Inc.' has realized cumulative trailing twelve months Operating Loss of $ -1 millions in the Mar 31 2018 period.
Rich Pharmaceuticals, Inc. achieved highest trailing twelve month year on year Operating Income growth. While overall Operating Income growth ranking, remained unchanged compare to the previous quarter at no. . |
Operating Income TTM Q/Q Growth Statistics |
High |
Average |
Low |
0 % |
0 % |
0 % |
|
|
|
|
|
Operating Income TTM Y/Y Growth Statistics |
High |
Average |
Low |
0 % |
0 % |
0 % |
|
|
|
Operating Income TTM Q/Q Growth Company Ranking |
Within: |
No. |
Industry |
# |
Sector |
# |
S&P 500 |
# |
|
Cumulative Operating Income growth
Comment |
Rich Pharmaceuticals, Inc.' has realized cumulative trailing twelve months Operating Loss of $ -1 millions in the Mar 31 2018 period.
Rich Pharmaceuticals, Inc. achieved highest trailing twelve month year on year Operating Income growth. While overall Operating Income growth ranking, remained unchanged compare to the previous quarter at no. . |
Operating Income TTM Q/Q Growth Statistics |
High |
Average |
Low |
0 % |
0 % |
0 % |
|
|
|
Operating Income TTM Y/Y Growth Statistics |
High |
Average |
Low |
0 % |
0 % |
0 % |
|
|
|
Operating Income TTM Q/Q Growth Company Ranking |
Within: |
No. |
Industry |
# |
Sector |
# |
S&P 500 |
# |
|